EUVIMEDEUVIMED entdecken
Open Access

Cell Surface Expression and PET Imaging Establish DLL3 as a Clinically Actionable Target in Neuroblastoma

Salvatore M Aspromonte, Tamar Y Feinberg, Somali Gavane, Candace Parker, Ali Cihan, Daoqi You, Salomon A Tendler, Jaime Alvarez-Perez, Samantha Brosius, Armaan Siddiquee, Dylan Domenico, Glorymar Ibañez und 21 weitere

Journal of Nuclear Medicine · 2026-11 · 67 (11) · 1755-1763

DOI: 10.2967/jnumed.126.272770 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 10.09.2026. Verfasst von Salvatore M Aspromonte und 32 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Neuroblastoma, Membrane Proteins, Positron-Emission Tomography, Intracellular Signaling Peptides and Proteins. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In adult neuroendocrine malignancies, including small cell lung cancer, Delta-like ligand 3 (DLL3) is a validated therapeutic target. DLL3 is expressed in neuroblastoma, a pediatric cancer of neuroendocrine origin, but subcellular localization is incompletely defined, limiting clinical translation of DLL3-targeted therapies for neuroblastoma.

Methods

DLL3 expression and localization were evaluated in human neuroblastoma tumors and preclinical models using RNA sequencing, immunohistochemistry, and flow cytometry. To assess in vivo tumor accessibility, DLL3-targeted PET imaging with [89Zr]Zr-deferoxamine-SC16.56 was performed in patient-derived xenograft (PDX) models and in 4 patients with neuroblastoma.

Results

DLL3 was broadly expressed across neuroblastoma tumor samples and preclinical models. Although immunohistochemistry demonstrated variable protein expression, flow cytometry revealed near-universal DLL3 cell surface localization across clinical samples and PDX models, including tumors with low expression by immunohistochemistry. DLL3-targeted PET imaging demonstrated tumor-specific uptake in PDX models and in 4 patients with relapsed neuroblastoma, confirming in vivo accessibility of DLL3.

Conclusion

DLL3 overexpression in neuroblastoma is associated with targetable cell surface localization, supporting DLL3 as a clinically actionable target for imaging and therapeutic strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaMembrane ProteinsPositron-Emission TomographyIntracellular Signaling Peptides and ProteinsGene Expression Regulation, NeoplasticCell MembraneHumansAnimalsMiceCell Line, TumorMaleFemale

Stichwörter der Autor:innen

DLL3PET imagingneuroblastoma

Substanzen

DLL3 protein, humanMembrane ProteinsIntracellular Signaling Peptides and Proteins

Autor:innen und Institutionen

  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiology, Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Immunology Program, Memorial Sloan Kettering Cancer Center, New York, New York.

Zitieren

APA

Aspromonte, S. M., Feinberg, T. Y., Gavane, S., Parker, C., Cihan, A., You, D., Tendler, S. A., Alvarez-Perez, J., Brosius, S., Siddiquee, A., Domenico, D., Ibañez, G., Stockfisch, E., Bean, J. M., Cochrane, A. M., Bhanot, U., Tickoo, S. K., Jungbluth, A., Frosina, D., …, & Kung, A. L. (2026). Cell Surface Expression and PET Imaging Establish DLL3 as a Clinically Actionable Target in Neuroblastoma. Journal of Nuclear Medicine, 67(11), 1755-1763. https://doi.org/10.2967/jnumed.126.272770

Vancouver

Aspromonte SM, Feinberg TY, Gavane S, Parker C, Cihan A, You D, et al. Cell Surface Expression and PET Imaging Establish DLL3 as a Clinically Actionable Target in Neuroblastoma. Journal of Nuclear Medicine. 2026;67(11):1755-1763. doi:10.2967/jnumed.126.272770

BibTeX
@article{Aspromonte2026,
  author = {Aspromonte, Salvatore M and Feinberg, Tamar Y and Gavane, Somali and Parker, Candace and Cihan, Ali and You, Daoqi and Tendler, Salomon A and Alvarez-Perez, Jaime and Brosius, Samantha and Siddiquee, Armaan and Domenico, Dylan and Ibañez, Glorymar and Stockfisch, Emily and Bean, James M and Cochrane, Anne M and Bhanot, Umesh and Tickoo, Satish K and Jungbluth, Achim and Frosina, Denise and Angelini, Paola and Shukla, Neerav and Lyashchenko, Serge K and Poirier, John T and Schoder, Heiko and Rudin, Charles M and Lewis, Jason S and Curran, Kevin J and Daniyan, Anthony and Dunphy, Mark P and Glade Bender, Julia L and Modak, Shakeel and Dela Cruz, Filemon S and Kung, Andrew L},
  title = {Cell Surface Expression and PET Imaging Establish DLL3 as a Clinically Actionable Target in Neuroblastoma},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  volume = {67},
  number = {11},
  pages = {1755--1763},
  doi = {10.2967/jnumed.126.272770}
}
Kostenlos starten →